Absstract of: WO2023003673A1

Systems and apparatuses for securing and protecting diabetes management devices, such as continuous glucose monitoring (CGM) devices and insulin infusion sets. An apparatus (10) comprises a base (20) having multiple pairs of arms which can be attached to a band. The apparatus (10) also comprises a shell (30) for retaining a diabetes management device and which may be unitarily formed with, or removably attached to, the base (20). A system may include an apparatus (510), a diabetes management device (501) retained in the shell (530) of the apparatus (510), and a band (540) attached to the base (530) of the apparatus (510). The band (540) may be placed around a body part of a user, such as an arm or the abdomen. A system can include an adhesive patch (750) having an adhesive layer overlaid with multiple liners (753A, 753B, 753C, 753D) having cutlines (755A, 755B, 755C, 755D) formed therebetween.

Absstract of: US2023022094A1

Dysglycemia as a risk factor for neurodevelopmental disorder or developmental diabetes. The risk is assessed based on measurement of a glucose control indicator in a blood sample. One particular example of a neurodevelopmental disorder is retinopathy of prematurity in an infant. One particular example of a glucose control indicator is ‘comprehensive glycated hemoglobin fraction’ or ‘comprehensive glycated albumin fraction.’ This is calculated using ‘total whole blood protein’ in the denominator. In the case of chronic hyperglycemia, there is an increased risk of proliferative retinopathy of prematurity. In the case of chronic hypoglycemia, there is an increased risk of non-proliferative retinopathy of prematurity. This ‘total whole blood protein’ technique could also be used to determine the glucose control status in other types of patients.

Absstract of: US2023029043A1

A device is disclosed that is configured as a fully autonomous and integrated wearable apparatus for diabetes management. The device comprise a self-pressurized reservoir for storing the medication for subsequent delivery to a patient, a needle for delivering the medication to the patient subcutaneously, a first MEMS device configured as a microvalve in a fluid path between the self-pressurized reservoir and needle for controlling flowrate of medication through the needle as the self-pressurized reservoir discharges, a second MEMS device configured as a micropump configured to increase flowrate of the medication in the fluid path to ensure a constant flowrate in the fluid path as the self-pressurized discharges independent of orientation of the device, a flow sensor configured to measure flowrate in the fluid path for controlling microvalve and micropump, and control circuitry connected to the microvalve, micropump and flow sensor for controlling operation of the micropump and microvalve.

Absstract of: US2023027609A1

Embodiments provide for methods, systems, apparatus and computer readable media for calibrating an analyte sensor upon insertion into tissue of a subject based at least in part on parameters obtained from another analyte sensor already calibrated and previously inserted into the tissue of the subject. As an example, a method may include predicting a background current associated with the newly inserted sensor, subtracting the background current from a current measured by the newly inserted sensor, and converting the subtracted current to a glucose value, the converting based at least in part on the parameters obtained from the previously inserted analyte sensor. In this way, the newly inserted sensor may be calibrated without relying on actual blood-based analyte measurements, and accuracy and sensitivity of the newly inserted sensor may be improved.

Absstract of: US2023024262A1

Methods, devices, and systems may use a kinetic model to determine physiological parameters related to the kinetics of red blood cell glycation, elimination, and generation. Such physiological parameters can be used, for example, to determine a more reliable calculated HbA1c. In another example, a method may comprise: receiving a plurality of glucose levels over a time period; receiving a glycated hemoglobin (HbA1c) level corresponding to an end of the time period; determining at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (kgly), a red blood cell generation rate constant (kgen), a red blood cell elimination constant (kage), and an apparent glycation constant (K), based on (1) the plurality of glucose levels and (2) the HbA1c level; and adjusting a glucose level target based on the at least one physiological parameter.

Absstract of: EP4122384A1

Methods, devices and systems related providing accurate glucose levels in view of temperatures that may adversely affect glucose value.

Absstract of: US2023018355A1

The disclosed embodiments are directed to methods for dynamically adjusting the total daily insulin requirements of a user during pregnancy, based on the gestational week. An initial estimate of the adjusted total daily insulin requirement may be calculated as a multiple of the pre-pregnancy total daily insulin requirement, based on an average scale factor from a population of pregnant women suffering from Type I diabetes mellitus. An automatic drug delivery device may adjust the initial estimate of the total daily insulin requirement based on blood glucose level readings from a continuous glucose monitor during the course of the pregnancy.

Absstract of: US2023013632A1

Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.

Absstract of: US2023017510A1

Electrochemical impedance spectroscopy (EIS) may be used in conjunction with continuous glucose monitoring (CGM) to enable identification of valid and reliable sensor data, as well implementation of Smart Calibration algorithms.

Absstract of: US2023017117A1

An infusion system to provide concurrent TPN/insulin infusion including: a fluid administration set having a primary line in fluid communication with the TPN source, a secondary line in fluid communication with the insulin source, and a common outlet line; a pump operable to removably receive the fluid administration set, the pump being operable to concurrently move the TPN solution through the primary line in response to a TPN solution flow rate signal and the insulin solution through the secondary line in response to an insulin solution flow rate signal; and a flow controller operable to provide the TPN solution flow rate signal and the insulin solution flow rate signal to the pump. The flow controller is further operable to vary the TPN solution flow rate signal and the insulin solution flow rate signal to vary a ratio of TPN solution to insulin solution provided to the common outlet line.

Absstract of: US2023016823A1

Sensors are disclosed that detect whether a cannula is properly inserted to its full depth in a subject's skin. The sensors may be used with a blood glucose monitor, or with a continuous insulin infusion pump, infusion set, or other system involving intermittent or continuous testing and/or drug delivery.

Absstract of: US11553861B1

The present development is a method and device to monitor the salt level in a patient's blood without the need of laboratory facilities or intervention by medical personnel. The basic device is designed to measure the concentration of analytes, specifically sodium ion and potassium ion, in the patient's blood and to communicate the analyte level to the patient essentially instantaneously through a mobile monitor or display screen. In a variation, the device combines the analyte-concentration measuring function with a means for measuring the concentration of glucose in blood, and the blood analyte level and glucose level are displayed to the patient essentially instantaneously. Both the salt level device and the salt level+glucose level device may be further adapted to allow for the salt and glucose level data to be stored in a data storage base so the patient has an historical record of the concentration levels.

Absstract of: WO2023280017A1

A non-invasive blood glucose meter comprises a housing (1), a controller (2), a power supply module (3), cooling fins (4), a power switch (5), an LED light source (6), and a spectral sensor (7). A finger compartment (8) is provided in the housing (1); the power supply module (3) and the controller (2) are electrically connected to each other and are disposed in the housing (1); the LED light source (6) is disposed at the end of the finger compartment (8) and is located on the top surface of the finger compartment (8); the cooling fins (4) are connected to the spectral sensor (7); the spectral sensor (7) is located at the end of the finger compartment (8) and located on the bottom surface of the finger compartment (8); the LED light source (6) and the spectral sensor (7) are located on a same straight line. During non-invasive blood glucose detection, position limit, classification and recognition, detection position determining, and fingertip pressing degree determining can be performed on the finger before non-invasive blood glucose detection, and most stable spectral detection is performed on the finger when all interference factors are minimized.

Absstract of: US2023011856A1

An arrangement for operating a biosensor emitting radiation includes an excitation light source, which generates at least one excitation radiation for the biosensor; a coupling fiber, at the entry surface of which the excitation radiation is coupled in; an optical Y-coupler, including an excitation arm, which is connected to the exit surface of the coupling fiber, a detector arm, which is connected to an optical detector, and a sensor foot, which can be connected to the biosensor. The excitation arm has a conical shape. The radiation axis of the excitation arm includes an angle in the range of 5° to 70° with the main radiation axis of the detector arm. The diameter of the excitation arm at the connecting point to the detector arm is less than two thirds the diameter of the detector arm. An arrangement for determining the glucose content blood is also provided.

Absstract of: US2023009339A1

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Some methods and systems may be configured to adjust insulin delivery to a person with diabetes according to one or more conditions of an insulin delivery device. Some methods and systems may be configured to enable a lock-out mode where adjustment to insulin delivery to personalize automated insulin delivery is restricted.

Absstract of: US2023009905A1

An apparatus for estimating blood glucose is provided. The apparatus for estimating blood glucose may include a spectrometer configured to measure a spectrum from an object, and a processor configured to monitor a change in a contact state between the object and the spectrometer, determine a calibration section based on the monitored change in the contact state, extract a background signal from a spectrum of the determined calibration section, and generate a personalized blood glucose estimation model based on the extracted background signal.

Absstract of: US2023007916A1

The present disclosure provides methods of processing data provided by a transcutaneous or subcutaneous analyte sensor utilizing different algorithms to strike a balance between signal responsiveness accompanied by signal noise and the introduction of error associated with that noise. The methods utilize the strengths of a lag correction algorithm and a smoothing algorithm to optimize the quality and value of the resulting data (glucose concentrations and the rates of change in glucose concentrations) to a continuous glucose monitoring system. Also provided are systems and kits.

Absstract of: US2023011699A1

Provided are techniques, devices and systems that include monitoring a trend of blood glucose measurement values over a series of measurement cycles. A processor may identify a potential excursion outside a range of a target blood glucose measurement value setting of a user based on the monitored trend. In response to the identified potential excursion, an alert may be generated to the user to consume rescue carbohydrates. In addition, the disclosed techniques may include a processor that assesses the factors related to a potential impending hypoglycemic event for a user. Based on a result of the assessment of the factors, the processor may determine whether the user is approaching the potential impending hypoglycemic event for the user. In response to a determination that the user is approaching the potential impending hypoglycemic event for the user, a number of rescue carbohydrates to suggest for consumption by the user may be determined.

Absstract of: US2023011504A1

The present disclosure relates to a liquid medicine injection device including a patch portion to which a sensor portion configured to measure blood glucose is detachable and in which an injection portion configured to inject a liquid medicine into the body of a user is installed, and a stamping portion on which the patch portion is mounted and including a first needle connectable to the sensor portion, wherein the stamping portion transmits power to the patch portion so that the first needle and a second needle, which is connected to the injection portion, are together inserted into the skin of the user, and the sensor portion and the injection portion are installed in a single device so that the convenience of use is improved when the liquid medicine injection device is attached to the skin of the user.

Absstract of: US2023008671A1

A wire-based three-pole sensor for subcutaneous insertion includes a working electrode including a first split wire having a first flat surface, and a support sheet on the first flat surface. The first flat surface is created from a full wire having a circular cross-section with a portion removed. A reference electrode includes a second split wire having a second flat surface. The second flat surface is defined by a second chord across a circular cross-section of the second split wire. A counter electrode includes a third split wire having a third flat surface. The third flat surface is defined by a third chord across a circular cross-section of the third split wire. The second and third flat surfaces face each other. A cross-sectional diameter of the first split wire, the second split wire, and the third split wire coupled together is less than an inner diameter of an insertion needle.

Absstract of: US2023008055A1

An integrated disease management system provides patients with simple, quick, and readily available counseling regarding a healthy diabetic lifestyle. The system can include an interactive engine with predictive analytics and machine learning to provide a customized experience for a user. The system can be configured to transmit data to a remote server to perform analysis of received data (e.g., disease management data), to provide feedback to the user (e.g., customized feedback with curated content based on a user's data and interface interactions) and send all or a portion of the data and/or curated content to another user device or remote health management access point (e.g., as cloud storage) where the information can be accessed by healthcare stakeholder.

Absstract of: US2023008094A1

In some examples, a system includes a glucose sensor configured to generate a signal indicative of a blood glucose level of a patient, a medical device configured to deliver insulin to the patient, a peritoneal dialysis (PD) device, and control circuitry. The control circuitry is configured to control the PD device to deliver PD therapy to a patient during a PD cycle, determine a blood glucose level of the patient during the PD cycle based on a signal from the glucose sensor, determine that the blood glucose level is greater than or equal to a predetermined blood glucose level threshold, and control the medical device to deliver insulin to the patient in response to determining the blood glucose level is greater than or equal to the predetermined blood glucose level threshold.

Absstract of: EP4115927A1

Provided is a liquid medication control injection device including a blood glucose measuring unit configured to measure blood glucose of target of injection at least a plurality of times, sequentially, a first liquid medication injection unit configured to inject a first liquid medication containing a component for controlling a decrease in blood glucose of the target of injection to the target of injection, and a second liquid medication injection unit configured to inject a second liquid medication containing a component for controlling an increase in blood glucose of the target of injection, wherein the component of the second liquid medication is different from that of the first liquid medication.

Absstract of: US2023000404A1

An electronic device, a method to be executed by an electronic device, and a non-transitory memory storing a program for causing an electronic device to execute processes include acquiring a pulse wave of a subject, and estimating a blood glucose level and/or a lipid level of the subject based on a displacement ratio in the pulse wave. The displacement ratio comprises a ratio between a displacement of the pulse wave at a peak of the pulse wave and a displacement of the pulse wave at a predetermined time after the peak of the pulse wave, and the predetermined time is a fixed value.

Absstract of: US2023000400A1

Glucose monitoring devices and related systems and methods, the glucose monitoring devices including a sensor electronics unit having a housing and a printed circuit board disposed within the housing, a transcutaneous glucose sensor assembly, and a conductive sensor connector. The printed circuit board includes a first electrical contact, the transcutaneous glucose sensor assembly includes a distal portion having a working electrode and proximal portion having a working-electrode contact in electrical communication with the working electrode, and the conductive sensor connector electrically connects the working-electrode contact with the first electrical contact. Further, the conductive sensor connector extends through a hole in the proximal portion of the transcutaneous glucose sensor assembly and through a hole in the printed circuit board.